[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"LTS Therapy Systems, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":76},{"warningLetters":4,"total":75},[5,31,52],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},717,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-08-12T04:00:00Z\">08\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-22T04:00:00Z\">07\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectra-therapy-llc-698026-07222025\">Spectra Therapy, LLC \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John J. Stephan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Spectra Therapy, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3350 Lapeer Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Huron\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48060\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:johnstephan@spectratherapy.com\"> johnstephan@spectratherapy.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS: 698026\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 22, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Stephan:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Port Huron, MI on September 10, 2024, through September 13, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures therapeutic heating infrared lamps, marketed as the LASERwrap system. The LASERwrap system includes the Spectra A-100 Impulse Laser Unit and accessories such as filament wraps and pads that are applied to the body and connected to the Spectra A-100 Impulse Laser Unit. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation Violation(s)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, dated September 24, 2024, but received October 3, 2024, on behalf of your firm, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met to demonstrate that the design was developed in accordance with the design control requirements as required by 21 CFR § 820.30(a) through § 820.30(j). Specifically,\u003C\u002Fp>\u003Cp>a. Your firm has not established procedures to control the design of the LASERwrap system.\u003C\u002Fp>\u003Cp>b. Your untitled and undated design document provided during the inspection did not provide adequate detail or objective evidence to demonstrate how the specific specifications and operating modes listed in this document were developed, established, verified, and validated to ensure that device conforms to user needs and the proper functioning of the device. Further, your firm was unable to provide evidence that software validation and\u002For risk analysis were performed.\u003C\u002Fp>\u003Cp>c. Several design changes have been made to the LASERwrap system that have not been verified and\u002For validated. For example, a design change to the housing (or case) of the A-100 Impulse Laser unit was made in 2021, and this design change was not verified and\u002For validated and was not conducted in accordance with any established procedure.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. This response promises development of a \u003Cem>Product Design and Development\u003C\u002Fem> procedure and plans to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> audit of devices already sold. Your firm’s response does not address how it will establish a design plan, inputs, outputs, verification, and validation for the LASERwrap system. It also does not address reviewing the design changes made to the device to determine if verification and\u002For validation is required. In your firm’s response to this letter, please address these concerns and provide a copy of the promised procedure, complete documentation for all design control requirements of the LASERwrap system, and the outcome of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> audit once these items are completed or a timeframe when these items will be provided.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR § 820.90.\u003C\u002Fp>\u003Cp>Specifically, your firm has not established a procedure to control nonconforming product found during final acceptance activities. For example, when a laser is found to not conform to specified requirements as part of your final functional testing, your manager stated that it is placed into a “Lasers need repair” bin with details related to the nonconformance occasionally captured on pieces of \u003Cstrong>(b)(4)\u003C\u002Fstrong> paper. This bin is subsequently returned to your firm’s contract manufacturer to perform investigation and repair without documentation of these activities.\u003C\u002Fp>\u003Cp>Your firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR § 820.100.\u003C\u002Fp>\u003Cp>Specifically, your firm’s corrective and preventive procedure, BSP-05 Corrective and Preventative Actions Procedure, has not been implemented and remains in a draft status.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. In this response your firm indicates that it plans to complete and initiate a “Corrective Action\u002FPreventive Action” (CAPA) procedure to address this observation. Please provide this procedure for our review.\u003C\u002Fp>\u003Cp>4. Failure to maintain an adequate record of investigation as required by 21 CFR § 820.198(e). The record of investigation shall include:\u003C\u002Fp>\u003Cp>a. The name of the device;\u003Cbr>b. The date the complaint was received;\u003Cbr>c. Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used;\u003Cbr>d. The name, address, and phone number of the complainant;\u003Cbr>e. The nature and details of the complaint;\u003Cbr>f. The dates and results of the investigation;\u003Cbr>g. Any corrective action taken; and\u003Cbr>h. Any reply to the complainant.\u003C\u002Fp>\u003Cp>Specifically, your firm has failed to document investigations performed by your firm and\u002For contract manufacturers utilized by your firm that contain the above required information. For example, you provided a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” spreadsheet that your firm utilizes to log complaints received as well as lasers returned to your firm. This document contains approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines of complaints received over a \u003Cstrong>(b)(4)\u003C\u002Fstrong>-month period. However, this document is not being adequately maintained in that several rows are blank and missing the above required information.\u003C\u002Fp>\u003Cp>Your firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\u003C\u002Fp>\u003Cp>5. Failure to evaluate and select potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements. The evaluation shall be documented, as required by 21 CFR § 820.50(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your firm’s purchasing control procedure (BSP-03 Purchasing Controls Procedure; no Rev.; no date) includes the following requirements:\u003C\u002Fp>\u003Cp>a. Section 4.2.1C requires a copy of the vendor’s ISO 134865 or ISO 9001 certification of registration OR results of the vendor’s self-assessment conducting in accordance with their Quality Management System.\u003C\u002Fp>\u003Cp>Documented proof of these documents or any other documented vendor selection and evaluation was not provided.\u003C\u002Fp>\u003Cp>b. Section 4.4.1 of your purchasing control procedure requires your firm to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> vendor evaluations to review the suppliers’ performance.\u003C\u002Fp>\u003Cp>Documented incidences of periodic reviews being conducted were not provided.\u003C\u002Fp>\u003Cp>However, despite no initial or periodic evaluation of your suppliers being performed, all suppliers are listed as ‘Active’ on your firm’s qualified supplier list (Production Supplier List; Effective 9-1-2024).\u003C\u002Fp>\u003Cp>Your firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR § 820.80(d).\u003C\u002Fp>\u003Cp>Specifically, your firm’s manager explained that she is responsible for performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing of finished devices. This process and activities are not performed according to an established procedure or work instruction, nor are the results of these activities documented.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm’s response indicates it will create documents for acceptance activities. Please provide these acceptance activity documents for our review.\u003C\u002Fp>\u003Cp>7. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR § 820.22.\u003C\u002Fp>\u003Cp>Specifically, your firm has not established procedures for quality audits, nor have you conducted a quality audit since your firm began manufacturing devices in 2008.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. In this response you indicate that your firm will initiate a quality audit as soon as possible and provide procedures and associated forms (“Quality Audits”) with an estimated completion date of 11-29-2024. However, these promised documents have not been provided. In your response to this letter, provide the promised forms or a date that they will be provided. Additionally, provide evidence of a quality audit or the date one is planned.\u003C\u002Fp>\u003Cp>8. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure that the quality system satisfies the requirements of this part and the manufacturer's established quality policy and objectives, as required by 21 CFR § 820.20(c).\u003C\u002Fp>\u003Cp>Specifically, your firm has not established procedures for conducting management reviews nor have you conducted a management review since your firm began manufacturing devices in 2008.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. In this response you indicate that your firm will provide procedures and associated forms (“Management Review”) with an estimated completion date of 12-31-2024. However, these promised documents have not been provided. In your response to this letter, provide the promised forms or a date that they will be provided. Additionally, your response does not address if your firm plans to conduct a management review. Please explain if one has been conducted or the date one is planned.\u003C\u002Fp>\u003Cp>9. Failure to establish and maintain procedures to control all documents, as required by 21 CFR § 820.40.\u003C\u002Fp>\u003Cp>Specifically, your firm has not established procedures to control documents (policies, procedures, forms, etc.) utilized by your firm for the operations related to medical devices manufactured by your firm.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. In this response your firm indicated that it would complete and initiate a “Document Control” procedure with an estimated completion date of 12-31-2024. In your response to this letter, provide the promised document or a date that they will be provided.\u003C\u002Fp>\u003Cp>10. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities. Training shall be documented, as required by 21 CFR § 820.25(b).\u003C\u002Fp>\u003Cp>Specifically, your firm has not established a training procedure nor has training been documented for any employee.\u003C\u002Fp>\u003Cp>Your firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that the LASERwrap system is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as you market it.\u003C\u002Fp>\u003Cp>The LASERwrap system is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device, intended for a use different from the intended use of a legally marketed device in the generic type of device described under 21 CFR 890.5500 Infrared lamp without submitting a premarket notification to FDA as required by section 510(k) of the Act and 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Devices classified under 21 CFR 890.5500 Infrared lamp are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). Generic devices of this type emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain.\u003C\u002Fp>\u003Cp>There is evidence that the LASERwrap system is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5500 (Infrared lamp). Based on the user manual collected during the inspection and a review of your firm’s website, https:\u002F\u002Fspectratherapy.com\u002Fhuman-treatable-%20%20%20conditions\u002F (accessed July 9, 2025) your firm is marketing the LASERwrap system for different intended uses, including treatment of diseases or conditions such as irritable bowel syndrome, wounds, and urinary tract infections, and cure of “inflammatory issues” such as tendonitis, bursitis, and plantar fasciitis. For example, the product user manual includes the following claims:\u003C\u002Fp>\u003Cp>• “The Physiological Effects of [Low-level laser therapy] LLLT are:\u003Cbr>1. Bio-stimulation\u003Cbr>&nbsp;  Improved metabolism\u003Cbr>&nbsp;  Increase of cell metabolism\u003Cbr>. . .\u003Cbr>5. Stimulation of wound healing…”\u003C\u002Fp>\u003Cp>• “How has LLLT worked for others? . . .\u003Cbr>&nbsp; o Increases . . . tensile strength of tissue repair\u003Cbr>&nbsp; o Stimulates the immune system and nerve function\u003Cbr>&nbsp; o Develops collagen ...\u003Cbr>&nbsp; o Promotes faster wound healing and clot formation ...”\u003C\u002Fp>\u003Cp>• “Abdominal &amp; Back LASERwrap® Treatments ...\u003Cbr>&nbsp; o Reduce IBS [Irritable Bowel Syndrome] &amp; UTI [Urinary Tract Infection]”\u003C\u002Fp>\u003Cp>Your website also https:\u002F\u002Fspectratherapy.com\u002Fhuman-treatable-%20%20%20conditions\u002F includes the following statements:\u003C\u002Fp>\u003Cp>• Under “Wounds” your website provides the following testimonial: “LASERwrap® eliminated PAIN from 7 patients in less than a week to 10 days, that had been fighting neuropathy &amp; plantar fasciitis conditions from 6 MONTHS to 2 YEARS. Good news for lower extremity diabetic patients with wounds on the bottom of their feet, LASERwrap® healed decubitus wounds in 2 weeks versus 4-5 months using conventional debriefing methods.”\u003C\u002Fp>\u003Cp>• Under “Chronic Pain” your website provides the following testimonial: “This laser has a multiplicity of effects. It can cure both acute and chronic inflammatory issues including tendonitis, ankle sprains, bursitis, plantar fasciitis and back strain all without the use of anti-inflammatory or pain medicine. It can markedly decrease the pain of neuropathy in the lower extremeities [sic] and improve restless leg syndrome to the pint [sic] where patients can eliminate medication. It can decrease the time it takes to heal stasis and vascular ulders [sic]...”\u003C\u002Fp>\u003Cp>• Under “Fibromyalgia” your website provides the following testimonial: “...The most common types include osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), fibromyalgia and gout. Since all of them cause pain in different ways, LASERwrap® treats a large AREA of concern, rather than just a small spot of interest, providing improved circulation around the entire extremity, across shoulders &amp; neck or entire lower back &amp; sciatica area.”\u003C\u002Fp>\u003Cp>• Fractures\u003Cbr>• Insomnia\u003Cbr>• Migraines\u003Cbr>• Oral...Pain\u003Cbr>• Respiratory (COPD)\u003Cbr>• Spine Injuries\u003Cbr>• TMJ\u002FTMD Disorder\u003C\u002Fp>\u003Cp>Because there is evidence as described above that the LASERwrap system is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5500, the device exceeds the limitations described in 21 CFR 890.9(a) and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>Further, FDA cleared a 510(k) (K080689) for the “Spectra Therapy Spectra A1000 Laser Device” on July 9, 2008, with the following indications for use: “The Spectra Therapy Spectra A1000” is an infrared lamp intended to provide topical heating . . . [and] is indicated for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm, relieving stiffness, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation where heat is indicated.” However, the statements in your firm’s user manual for the LASERwrap system and on your firm’s website provide evidence that the device is intended to treat diseases or conditions such as irritable bowel syndrome, wounds, and urinary tract infections, and to cure “inflammatory issues” such as tendonitis, bursitis, and plantar fasciitis, which would constitute a major change or modification to the intended use of the device cleared under K080689, for which your firm lacks clearance or approval. Examples of these statements are included above.\u003C\u002Fp>\u003Cp>Your firm has provided no evidence to FDA supporting the above listed claims. The lack of supporting information demonstrating the safety and effectiveness of your device raises public health concerns, including the risk of a delay in definitive treatment if the LASERwrap systems are used as advertised. For example, delayed or ineffective treatment for wound care can lead to tissue death, infection, amputation, or death. Additionally, delayed or ineffective treatment of neuropathy can lead to permanent nerve damage and loss of function.\u003C\u002Fp>\u003Cp>Your firm’s response did not address your firm’s marketing of the LASERwrap system for intended uses that are different from the intended use of legally marketed devices classified under 21 CFR 890.5500.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there is a failure or refusal to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting.\u003C\u002Fp>\u003Cp>During the inspection, your firm identified the document titled “BSP-02 Medical Device Reporting (MDR) Procedure,” undated, as its written MDR procedure.\u003C\u002Fp>\u003Cp>After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1. BSP-02 Medical Device Reporting (MDR) Procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\u003Cp>a. There are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that your procedure does not include definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>b. There are no instructions for how the firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\u003Cp>2. BSP-02 Medical Device Reporting (MDR) Procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\u003C\u002Fp>\u003Cp>a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event as required under 21 CFR 803.50(b)(3).\u003C\u002Fp>\u003Cp>b. BSP-02 Medical Device Reporting (MDR) Procedure, as written, does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\u003Cp>3. BSP-02 Medical Device Reporting (MDR) Procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the following are not addressed:\u003C\u002Fp>\u003Cp>a. Instructions for how to obtain and complete the MedWatch for Industry FDA 3500A form, including which sections of the 3500A form will need to be completed to include all the information found in the firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\u003C\u002Fp>\u003Cp>b. The circumstances under which the firm must submit an initial report, supplemental or follow-up report, 5-day reports and the requirements for such reports.\u003C\u002Fp>\u003Cp>c. A process for submitting initial reports and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a)\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>4. BSP-02 Medical Device Reporting (MDR) Procedure does not describe how the firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\u003C\u002Fp>\u003Cp>a. Documentation of adverse event related information maintained as MDR event files.\u003C\u002Fp>\u003Cp>b. Information that was evaluated to determine if an event was reportable.\u003C\u002Fp>\u003Cp>c. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable.\u003C\u002Fp>\u003Cp>d. Systems that ensure access to information that facilitates timely follow-up and inspection by FDA.\u003C\u002Fp>\u003Cp>Your firm’s response did not include actions that you have completed, nor did it include information addressing the procedural deficiencies listed above. Instead, your firm listed planned actions, only one of which listed a date, December 31, 2024, by which the firm would “attempt” to complete and initiate a “Product Design and Development” procedure.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The LASERwrap system is also misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Spectra Therapy, LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>Our office requests that Spectra Therapy, LLC cease any activities that result in the misbranding or adulteration of the LASERwrap system such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line \u003Cstrong>CMS Case 698026\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Information about the Final Rule for eMDR and the eMDR set-up process can be found on the FDA website at: eMDR – Electronic Medical Device Reporting | FDA\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJohn J. Stephan\n\nRecipient Title\n\nPresident & CEO\n\nSpectra Therapy, LLC\n\n3350 Lapeer Road\n\nPort Huron, MI 48060\n\nUnited States\n\njohnstephan@spectratherapy.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS: 698026\nJuly 22, 2025\nDear Mr. Stephan:\nDuring an inspection of your firm located in Port Huron, MI on September 10, 2024, through September 13, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures therapeutic heating infrared lamps, marketed as the LASERwrap system. The LASERwrap system includes the Spectra A-100 Impulse Laser Unit and accessories such as filament wraps and pads that are applied to the body and connected to the Spectra A-100 Impulse Laser Unit. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from (b)(6), (b)(7)(C), dated September 24, 2024, but received October 3, 2024, on behalf of your firm, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met to demonstrate that the design was developed in accordance with the design control requirements as required by 21 CFR § 820.30(a) through § 820.30(j). Specifically,\na. Your firm has not established procedures to control the design of the LASERwrap system.\nb. Your untitled and undated design document provided during the inspection did not provide adequate detail or objective evidence to demonstrate how the specific specifications and operating modes listed in this document were developed, established, verified, and validated to ensure that device conforms to user needs and the proper functioning of the device. Further, your firm was unable to provide evidence that software validation and\u002For risk analysis were performed.\nc. Several design changes have been made to the LASERwrap system that have not been verified and\u002For validated. For example, a design change to the housing (or case) of the A-100 Impulse Laser unit was made in 2021, and this design change was not verified and\u002For validated and was not conducted in accordance with any established procedure.\nWe reviewed your firm’s response and concluded that it is not adequate. This response promises development of a Product Design and Development procedure and plans to conduct (b)(4) audit of devices already sold. Your firm’s response does not address how it will establish a design plan, inputs, outputs, verification, and validation for the LASERwrap system. It also does not address reviewing the design changes made to the device to determine if verification and\u002For validation is required. In your firm’s response to this letter, please address these concerns and provide a copy of the promised procedure, complete documentation for all design control requirements of the LASERwrap system, and the outcome of the (b)(4) audit once these items are completed or a timeframe when these items will be provided.\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR § 820.90.\nSpecifically, your firm has not established a procedure to control nonconforming product found during final acceptance activities. For example, when a laser is found to not conform to specified requirements as part of your final functional testing, your manager stated that it is placed into a “Lasers need repair” bin with details related to the nonconformance occasionally captured on pieces of (b)(4) paper. This bin is subsequently returned to your firm’s contract manufacturer to perform investigation and repair without documentation of these activities.\nYour firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\n3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR § 820.100.\nSpecifically, your firm’s corrective and preventive procedure, BSP-05 Corrective and Preventative Actions Procedure, has not been implemented and remains in a draft status.\nWe reviewed your firm’s response and concluded that it is not adequate. In this response your firm indicates that it plans to complete and initiate a “Corrective Action\u002FPreventive Action” (CAPA) procedure to address this observation. Please provide this procedure for our review.\n4. Failure to maintain an adequate record of investigation as required by 21 CFR § 820.198(e). The record of investigation shall include:\na. The name of the device;\nb. The date the complaint was received;\nc. Any unique device identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s) used;\nd. The name, address, and phone number of the complainant;\ne. The nature and details of the complaint;\nf. The dates and results of the investigation;\ng. Any corrective action taken; and\nh. Any reply to the complainant.\nSpecifically, your firm has failed to document investigations performed by your firm and\u002For contract manufacturers utilized by your firm that contain the above required information. For example, you provided a “(b)(4)” spreadsheet that your firm utilizes to log complaints received as well as lasers returned to your firm. This document contains approximately (b)(4) lines of complaints received over a (b)(4)-month period. However, this document is not being adequately maintained in that several rows are blank and missing the above required information.\nYour firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\n5. Failure to evaluate and select potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements. The evaluation shall be documented, as required by 21 CFR § 820.50(a)(1).\nSpecifically, your firm’s purchasing control procedure (BSP-03 Purchasing Controls Procedure; no Rev.; no date) includes the following requirements:\na. Section 4.2.1C requires a copy of the vendor’s ISO 134865 or ISO 9001 certification of registration OR results of the vendor’s self-assessment conducting in accordance with their Quality Management System.\nDocumented proof of these documents or any other documented vendor selection and evaluation was not provided.\nb. Section 4.4.1 of your purchasing control procedure requires your firm to perform (b)(4) vendor evaluations to review the suppliers’ performance.\nDocumented incidences of periodic reviews being conducted were not provided.\nHowever, despite no initial or periodic evaluation of your suppliers being performed, all suppliers are listed as ‘Active’ on your firm’s qualified supplier list (Production Supplier List; Effective 9-1-2024).\nYour firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\n6. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR § 820.80(d).\nSpecifically, your firm’s manager explained that she is responsible for performing (b)(4) testing of finished devices. This process and activities are not performed according to an established procedure or work instruction, nor are the results of these activities documented.\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm’s response indicates it will create documents for acceptance activities. Please provide these acceptance activity documents for our review.\n7. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR § 820.22.\nSpecifically, your firm has not established procedures for quality audits, nor have you conducted a quality audit since your firm began manufacturing devices in 2008.\nWe reviewed your firm’s response and concluded that it is not adequate. In this response you indicate that your firm will initiate a quality audit as soon as possible and provide procedures and associated forms (“Quality Audits”) with an estimated completion date of 11-29-2024. However, these promised documents have not been provided. In your response to this letter, provide the promised forms or a date that they will be provided. Additionally, provide evidence of a quality audit or the date one is planned.\n8. Failure of management with executive responsibility to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure that the quality system satisfies the requirements of this part and the manufacturer's established quality policy and objectives, as required by 21 CFR § 820.20(c).\nSpecifically, your firm has not established procedures for conducting management reviews nor have you conducted a management review since your firm began manufacturing devices in 2008.\nWe reviewed your firm’s response and concluded that it is not adequate. In this response you indicate that your firm will provide procedures and associated forms (“Management Review”) with an estimated completion date of 12-31-2024. However, these promised documents have not been provided. In your response to this letter, provide the promised forms or a date that they will be provided. Additionally, your response does not address if your firm plans to conduct a management review. Please explain if one has been conducted or the date one is planned.\n9. Failure to establish and maintain procedures to control all documents, as required by 21 CFR § 820.40.\nSpecifically, your firm has not established procedures to control documents (policies, procedures, forms, etc.) utilized by your firm for the operations related to medical devices manufactured by your firm.\nWe reviewed your firm’s response and concluded that it is not adequate. In this response your firm indicated that it would complete and initiate a “Document Control” procedure with an estimated completion date of 12-31-2024. In your response to this letter, provide the promised document or a date that they will be provided.\n10. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities. Training shall be documented, as required by 21 CFR § 820.25(b).\nSpecifically, your firm has not established a training procedure nor has training been documented for any employee.\nYour firm’s response did not address this violation that was presented as a discussion item during the inspection. In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\nUnapproved Device Violation(s)\nOur inspection also revealed that the LASERwrap system is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as you market it.\nThe LASERwrap system is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device, intended for a use different from the intended use of a legally marketed device in the generic type of device described under 21 CFR 890.5500 Infrared lamp without submitting a premarket notification to FDA as required by section 510(k) of the Act and 21 U.S.C. § 360(k).\nDevices classified under 21 CFR 890.5500 Infrared lamp are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). Generic devices of this type emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain.\nThere is evidence that the LASERwrap system is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5500 (Infrared lamp). Based on the user manual collected during the inspection and a review of your firm’s website, https:\u002F\u002Fspectratherapy.com\u002Fhuman-treatable-%20%20%20conditions\u002F (accessed July 9, 2025) your firm is marketing the LASERwrap system for different intended uses, including treatment of diseases or conditions such as irritable bowel syndrome, wounds, and urinary tract infections, and cure of “inflammatory issues” such as tendonitis, bursitis, and plantar fasciitis. For example, the product user manual includes the following claims:\n• “The Physiological Effects of [Low-level laser therapy] LLLT are:\n1. Bio-stimulation\n Improved metabolism\n Increase of cell metabolism\n. . .\n5. Stimulation of wound healing…”\n• “How has LLLT worked for others? . . .\no Increases . . . tensile strength of tissue repair\no Stimulates the immune system and nerve function\no Develops collagen ...\no Promotes faster wound healing and clot formation ...”\n• “Abdominal & Back LASERwrap® Treatments ...\no Reduce IBS [Irritable Bowel Syndrome] & UTI [Urinary Tract Infection]”\nYour website also https:\u002F\u002Fspectratherapy.com\u002Fhuman-treatable-%20%20%20conditions\u002F includes the following statements:\n• Under “Wounds” your website provides the following testimonial: “LASERwrap® eliminated PAIN from 7 patients in less than a week to 10 days, that had been fighting neuropathy & plantar fasciitis conditions from 6 MONTHS to 2 YEARS. Good news for lower extremity diabetic patients with wounds on the bottom of their feet, LASERwrap® healed decubitus wounds in 2 weeks versus 4-5 months using conventional debriefing methods.”\n• Under “Chronic Pain” your website provides the following testimonial: “This laser has a multiplicity of effects. It can cure both acute and chronic inflammatory issues including tendonitis, ankle sprains, bursitis, plantar fasciitis and back strain all without the use of anti-inflammatory or pain medicine. It can markedly decrease the pain of neuropathy in the lower extremeities [sic] and improve restless leg syndrome to the pint [sic] where patients can eliminate medication. It can decrease the time it takes to heal stasis and vascular ulders [sic]...”\n• Under “Fibromyalgia” your website provides the following testimonial: “...The most common types include osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), fibromyalgia and gout. Since all of them cause pain in different ways, LASERwrap® treats a large AREA of concern, rather than just a small spot of interest, providing improved circulation around the entire extremity, across shoulders & neck or entire lower back & sciatica area.”\n• Fractures\n• Insomnia\n• Migraines\n• Oral...Pain\n• Respiratory (COPD)\n• Spine Injuries\n• TMJ\u002FTMD Disorder\nBecause there is evidence as described above that the LASERwrap system is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5500, the device exceeds the limitations described in 21 CFR 890.9(a) and is not exempt from premarket notification.\nFurther, FDA cleared a 510(k) (K080689) for the “Spectra Therapy Spectra A1000 Laser Device” on July 9, 2008, with the following indications for use: “The Spectra Therapy Spectra A1000” is an infrared lamp intended to provide topical heating . . . [and] is indicated for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm, relieving stiffness, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation where heat is indicated.” However, the statements in your firm’s user manual for the LASERwrap system and on your firm’s website provide evidence that the device is intended to treat diseases or conditions such as irritable bowel syndrome, wounds, and urinary tract infections, and to cure “inflammatory issues” such as tendonitis, bursitis, and plantar fasciitis, which would constitute a major change or modification to the intended use of the device cleared under K080689, for which your firm lacks clearance or approval. Examples of these statements are included above.\nYour firm has provided no evidence to FDA supporting the above listed claims. The lack of supporting information demonstrating the safety and effectiveness of your device raises public health concerns, including the risk of a delay in definitive treatment if the LASERwrap systems are used as advertised. For example, delayed or ineffective treatment for wound care can lead to tissue death, infection, amputation, or death. Additionally, delayed or ineffective treatment of neuropathy can lead to permanent nerve damage and loss of function.\nYour firm’s response did not address your firm’s marketing of the LASERwrap system for intended uses that are different from the intended use of legally marketed devices classified under 21 CFR 890.5500.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there is a failure or refusal to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting.\nDuring the inspection, your firm identified the document titled “BSP-02 Medical Device Reporting (MDR) Procedure,” undated, as its written MDR procedure.\nAfter reviewing the procedure, the following deficiencies were noted:\n1. BSP-02 Medical Device Reporting (MDR) Procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\na. There are inadequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that your procedure does not include definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. There are no instructions for how the firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n2. BSP-02 Medical Device Reporting (MDR) Procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event as required under 21 CFR 803.50(b)(3).\nb. BSP-02 Medical Device Reporting (MDR) Procedure, as written, does not specify who makes the decision for reporting events to FDA.\n3. BSP-02 Medical Device Reporting (MDR) Procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the following are not addressed:\na. Instructions for how to obtain and complete the MedWatch for Industry FDA 3500A form, including which sections of the 3500A form will need to be completed to include all the information found in the firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\nb. The circumstances under which the firm must submit an initial report, supplemental or follow-up report, 5-day reports and the requirements for such reports.\nc. A process for submitting initial reports and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a)1.\n4. BSP-02 Medical Device Reporting (MDR) Procedure does not describe how the firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\na. Documentation of adverse event related information maintained as MDR event files.\nb. Information that was evaluated to determine if an event was reportable.\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable.\nd. Systems that ensure access to information that facilitates timely follow-up and inspection by FDA.\nYour firm’s response did not include actions that you have completed, nor did it include information addressing the procedural deficiencies listed above. Instead, your firm listed planned actions, only one of which listed a date, December 31, 2024, by which the firm would “attempt” to complete and initiate a “Product Design and Development” procedure.\nUnique Device Identification Violation(s)\nThe LASERwrap system is also misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. Also, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Spectra Therapy, LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nOur office requests that Spectra Therapy, LLC cease any activities that result in the misbranding or adulteration of the LASERwrap system such as the commercial distribution of the device for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line CMS Case 698026 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\n_____________________\n1 Information about the Final Rule for eMDR and the eMDR set-up process can be found on the FDA website at: eMDR – Electronic Medical Device Reporting | FDA","Spectra Therapy, LLC","spectra-therapy-llc-698026-07222025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectra-therapy-llc-698026-07222025","2026-10-26T08:10:02.782423+00:00","Warning Letter","Issued","2025-08-12","698026","Medical Devices","John J. Stephan","2026-08-19T16:30:49.624+00:00","VIA Electronic Mail","2025-07-22",{"id":32,"raw":33,"subject":37,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":46,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":49,"issuing_office":11,"recipient_name":50,"body_fetched_at":51,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":47,"medical_device_id":19,"response_letter_date":19},3484,[34,35,36,11,37,13,38,13],"\u003Ctime datetime=\"2021-03-04T21:30:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthermoteknix-system-limited-613565-03042021\">Thermoteknix System Limited\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthermoteknix-systems-ltd-613565-03252025\">\u003Ctime datetime=\"2025-03-28T04:00:00Z\">03\u002F28\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Sydney Salisbury and Geraldine Anne Salisbury\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Thermoteknix System Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Teknix House, 2 Pembroke Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waterbeach, Cambridge\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>CB25 9QR\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Richard Sydney Salisbury\u003Cbr>\nGeraldine Anne Salisbury\u003Cbr>\nThermoteknix Systems Ltd\u003Cbr>\nTeknix House, 2 Pembroke Avenue\u003Cbr>\nWaterbeach, Cambridge\u003Cbr>\nCB25 9QR\u003Cbr>\nUNITED KINGDOM\u003C\u002Fp>\n\n\u003Cp>richard.salisbury@thermoteknix.com\u003Cbr>\ng.salisbury@thermoteknix.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp;&nbsp;\u003Cbr>\nRE:&nbsp;&nbsp;&nbsp;&nbsp; Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Mr. and Ms,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address (http:\u002F\u002Fwww.thermoteknix.com\u002F) on February 22, 2021.&nbsp; We have also reviewed your social media pages at https:\u002F\u002Ftwitter.com\u002FThermoteknix, https:\u002F\u002Fvimeo.com\u002Fthermoteknix, and https:\u002F\u002Fwww.facebook.com\u002FThermoteknix where you direct consumers to your website, https:\u002F\u002Fwww.thermoteknix.com. The FDA has observed that your website offers a product for measuring human body temperature, specifically the “FevIR Scan 2”, for sale in the United States. Based on our review, this product is intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Ca id=\"footnoteref1_zsxk64p\" href=\"#footnote1_zsxk64p\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; in people, and thus is a device under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the FevIR Scan 2 is intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“#COVID19 temperature screening &amp; face mask detection technology (FevIR Scan 2) from UK-based @Thermoteknix is helping keep American Bank customers &amp; staff safe during the pandemic.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1356643033559797761]\u003Cbr>\n•&nbsp;“FevIR Scan 2 has been specially engineered and developed in the UK by Cambridge-based thermal imaging experts Thermoteknix to help fight the spread of coronavirus and help businesses and industries around the world to stay open safely during the pandemic.” [Published on a blog post linked in http:\u002F\u002Fwww.thermoteknix.com\u002Fthermoteknix-temperature-screening-technology-becomes-american-banks-newest-front-line-defence-in-coronavirus-covid-19-fight\u002F]\u003Cbr>\n•&nbsp;“Face mask detection &amp; temperature screening. At the forefront during SARS &amp; Ebola viruses – now @Thermoteknix technology is helping curb the spread of #COVID19. Tech is helping us get back to the office safely &amp; back to doing business.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1352554113515577347]\u003C\u002Fp>\n\n\u003Cp>The FevIR Scan 2 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA.&nbsp; Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Ca id=\"footnoteref2_td9e6xe\" href=\"#footnote2_td9e6xe\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Ca id=\"footnoteref3_umdf6sn\" href=\"#footnote3_umdf6sn\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment.&nbsp; These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, \u003Ca href=\"http:\u002F\u002Fwww.thermoteknix.com\u002F\">http:\u002F\u002Fwww.thermoteknix.com\u002F\u003C\u002Fa>, includes statements that indicate that the FevIR Scan 2 is intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“On-screen and audible alerts identify one or more individuals in a large crowd situation with visible temperature tracking” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“FevIR Scan Fever Screening System is a skin temperature measurement system for mass screening of high pedestrian areas such as airports, train stations, factories and other public places” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”\u003Ca id=\"footnoteref4_0k8yac2\" href=\"#footnote4_0k8yac2\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa> provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to \u003C\u002Fstrong>\u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa> describing the specific steps you have taken to address these violations, using CMS # 613565 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp;&nbsp;&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_zsxk64p\">\u003Ca href=\"#footnoteref1_zsxk64p\">1\u003C\u002Fa>As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_td9e6xe\">\u003Ca href=\"#footnoteref2_td9e6xe\">2\u003C\u002Fa>Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_umdf6sn\">\u003Ca href=\"#footnoteref3_umdf6sn\">3\u003C\u002Fa>President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_0k8yac2\">\u003Ca href=\"#footnoteref4_0k8yac2\">4\u003C\u002Fa>Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload. \u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRichard Sydney Salisbury and Geraldine Anne Salisbury\n\nThermoteknix System Limited\n\nTeknix House, 2 Pembroke Avenue\n\nWaterbeach, Cambridge\n\nCB25 9QR\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nRichard Sydney Salisbury\n\nGeraldine Anne Salisbury\n\nThermoteknix Systems Ltd\n\nTeknix House, 2 Pembroke Avenue\n\nWaterbeach, Cambridge\n\nCB25 9QR\n\nUNITED KINGDOM\n\nrichard.salisbury@thermoteknix.com\n\ng.salisbury@thermoteknix.com\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Mr. and Ms,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address (http:\u002F\u002Fwww.thermoteknix.com\u002F) on February 22, 2021. We have also reviewed your social media pages at https:\u002F\u002Ftwitter.com\u002FThermoteknix, https:\u002F\u002Fvimeo.com\u002Fthermoteknix, and https:\u002F\u002Fwww.facebook.com\u002FThermoteknix where you direct consumers to your website, https:\u002F\u002Fwww.thermoteknix.com. The FDA has observed that your website offers a product for measuring human body temperature, specifically the “FevIR Scan 2”, for sale in the United States. Based on our review, this product is intended to mitigate, prevent, treat, diagnose or cure COVID-191 in people, and thus is a device under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the FevIR Scan 2 is intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\n• “#COVID19 temperature screening & face mask detection technology (FevIR Scan 2) from UK-based @Thermoteknix is helping keep American Bank customers & staff safe during the pandemic.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1356643033559797761]\n\n• “FevIR Scan 2 has been specially engineered and developed in the UK by Cambridge-based thermal imaging experts Thermoteknix to help fight the spread of coronavirus and help businesses and industries around the world to stay open safely during the pandemic.” [Published on a blog post linked in http:\u002F\u002Fwww.thermoteknix.com\u002Fthermoteknix-temperature-screening-technology-becomes-american-banks-newest-front-line-defence-in-coronavirus-covid-19-fight\u002F]\n\n• “Face mask detection & temperature screening. At the forefront during SARS & Ebola viruses – now @Thermoteknix technology is helping curb the spread of #COVID19. Tech is helping us get back to the office safely & back to doing business.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1352554113515577347]\n\nThe FevIR Scan 2 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, http:\u002F\u002Fwww.thermoteknix.com\u002F, includes statements that indicate that the FevIR Scan 2 is intended to scan multiple individuals simultaneously, including:\n\n• “On-screen and audible alerts identify one or more individuals in a large crowd situation with visible temperature tracking” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\n\n• “FevIR Scan Fever Screening System is a skin temperature measurement system for mass screening of high pedestrian areas such as airports, train stations, factories and other public places” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”4 provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613565 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n1As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload.","Thermoteknix System Limited","thermoteknix-system-limited-613565-03042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthermoteknix-system-limited-613565-03042021","2026-10-26T08:10:11.437986+00:00","Closed Out","2021-03-04","613565","2025-03-28","Richard Sydney Salisbury and Geraldine Anne Salisbury","2026-08-20T03:19:37.367+00:00",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":19,"issuing_office":58,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":73,"action_taken_date":74,"medical_device_id":19,"response_letter_date":19},329,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-11T05:00:00Z\">02\u002F11\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdynamic-stem-cell-therapy-712579-02112026\">Dynamic Stem Cell Therapy\u003C\u002Fa>","Center for Biologics Evaluation and Research","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-712579\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dale Carrison, D.O., FACEP, FACOEP\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dynamic Stem Cell Therapy\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2551 N. Green Valley Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Building C, Suite 305C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Henderson\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89014\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Contact@stemcellpowernow.com\"> Contact@stemcellpowernow.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 11, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-712579\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Carrison:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), through which your company markets an umbilical cord-derived stem cell product for allogeneic use (hereinafter, “your umbilical-cord derived product”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your misbranding of your umbilical-cord derived product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), your umbilical-cord derived product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example, you make the following claims about stem cells (which you state are used to make your umbilical-cord derived product):\u003C\u002Fp>\u003Cul>\u003Cli>Under a title of Regenerative Medicine for Sports Injuries, “There are a number of different types of sports injuries that can be treated with stem cells, including:\u003Cbr>o Knee injuries such as ligament tears and cartilage damage\u003Cbr>o Shoulder injuries such as rotator cuff tears and bursitis\u003Cbr>o Ankle and foot injuries such as ankle sprains and Achilles tendon ruptures\u003Cbr>o Hip injuries such as hip labral tears and arthritis\u003Cbr>o Muscle strains and tears”\u003C\u002Fli>\u003Cli>Under a title of Anti-Aging Stem Cell Therapy, “Anti-aging isn't the only amazing thing stem cell therapy can do--it has also been shown to improve various conditions resulting from injuries, like knee pain, spinal cord injury, joint pain, cardiovascular disease, and arthritis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your umbilical-cord derived product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Dynamic Stem Cell Therapy does not qualify for any exception in 21 CFR 1271.15, and your umbilical-cord derived product fails to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your umbilical-cord derived product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your umbilical-cord derived product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical-cord derived product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your umbilical-cord derived product is intended for use in the treatment of cardiovascular disease or arthritis, for example, which is not a basic function of the human umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your umbilical-cord derived product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is a misbranded drug under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your umbilical-cord derived product safely for its intended purposes. Accordingly, your umbilical-cord derived product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). Misbranding your umbilical-cord derived product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>Your umbilical-cord derived product is not the subject of an approved biologics license application (BLA) under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. If your umbilical-cord derived product was the subject of an approved BLA and labeled consistent with the approval, it would bear adequate directions for its intended uses, and subject to exceptions not applicable here, it could be lawfully introduced or delivered for introduction into interstate commerce.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concern\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are subject to requirements for drugs, as defined in section 201(g)(1) of the FD&amp;C Act, and biological products under section 351 of the PHS Act, including applicable premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your umbilical-cord derived product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your umbilical-cord derived product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your umbilical-cord derived product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-712579\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDale Carrison, D.O., FACEP, FACOEP\n\nRecipient Title\n\nMedical Director\n\nDynamic Stem Cell Therapy\n\n2551 N. Green Valley Parkway\n\nBuilding C, Suite 305C\n\nHenderson, NV 89014\n\nUnited States\n\nContact@stemcellpowernow.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nFebruary 11, 2026\nCBER 25-712579\nDear Dr. Carrison:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), through which your company markets an umbilical cord-derived stem cell product for allogeneic use (hereinafter, “your umbilical-cord derived product”).\nThis letter is to advise you that your misbranding of your umbilical-cord derived product while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, https:\u002F\u002Fstemcellpowernow.com (last visited February 2026), your umbilical-cord derived product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example, you make the following claims about stem cells (which you state are used to make your umbilical-cord derived product):\nUnder a title of Regenerative Medicine for Sports Injuries, “There are a number of different types of sports injuries that can be treated with stem cells, including:\no Knee injuries such as ligament tears and cartilage damage\no Shoulder injuries such as rotator cuff tears and bursitis\no Ankle and foot injuries such as ankle sprains and Achilles tendon ruptures\no Hip injuries such as hip labral tears and arthritis\no Muscle strains and tears”\nUnder a title of Anti-Aging Stem Cell Therapy, “Anti-aging isn't the only amazing thing stem cell therapy can do--it has also been shown to improve various conditions resulting from injuries, like knee pain, spinal cord injury, joint pain, cardiovascular disease, and arthritis.”\nTherefore, your umbilical-cord derived product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour umbilical-cord derived product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Dynamic Stem Cell Therapy does not qualify for any exception in 21 CFR 1271.15, and your umbilical-cord derived product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your umbilical-cord derived product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your umbilical-cord derived product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical-cord derived product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your umbilical-cord derived product is intended for use in the treatment of cardiovascular disease or arthritis, for example, which is not a basic function of the human umbilical cord in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your umbilical-cord derived product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour umbilical-cord derived product is a misbranded drug under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour umbilical-cord derived product is intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your umbilical-cord derived product safely for its intended purposes. Accordingly, your umbilical-cord derived product fails to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). Misbranding your umbilical-cord derived product while it is held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nYour umbilical-cord derived product is not the subject of an approved biologics license application (BLA) under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. If your umbilical-cord derived product was the subject of an approved BLA and labeled consistent with the approval, it would bear adequate directions for its intended uses, and subject to exceptions not applicable here, it could be lawfully introduced or delivered for introduction into interstate commerce.\nAdditional Concern\nIn addition to the violations described above, we offer the following comment:\nFDA’s review of your website also found that you market exosomes. As a general matter, exosomes intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body are subject to requirements for drugs, as defined in section 201(g)(1) of the FD&C Act, and biological products under section 351 of the PHS Act, including applicable premarket review and approval requirements. We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your umbilical-cord derived product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your umbilical-cord derived product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 Because your umbilical-cord derived product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Dynamic Stem Cell Therapy","dynamic-stem-cell-therapy-712579-02112026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdynamic-stem-cell-therapy-712579-02112026","2026-10-26T08:08:28.902666+00:00","2026-02-24","712579","Biologics","Dale Carrison, D.O., FACEP, FACOEP","2026-08-19T04:56:57.212+00:00","VIA UPS and Electronic Mail","CBER 25-712579","2026-02-11",3,{"510k":77,"classification":78,"enforcement":79,"event":80,"event_backfill":81,"pma":82,"warning_letter":83},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]